T-Bon

Quick links to important sections

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of T-Bon

This section provides a clear, foundational overview of T-Bon, defining its identity, composition, and general purpose based on the properties of its active ingredient, Calcium Carbonate.

Property Description
Active Ingredient Calcium Carbonate
Form Oral Tablet, Chewable Tablet, or Capsule
Pharmacological Class Mineral Supplement and Antacid
Common Use Mineral Replenishment and Gastric Acid Neutralization
Origin Inorganic Mineral Derivative

What Type of Agent is T-Bon and What is its Core Identity?

T-Bon is classified as a single-ingredient pharmaceutical preparation that acts as a dual-action pharmacological agent, serving primarily as an Essential Mineral Supplement and secondarily as an Antacid. Its identity is established by the active substance, Calcium Carbonate, which supports both fundamental physiological processes and provides immediate localized relief. Calcium Carbonate is utilized for its therapeutic action as an electrolyte replenisher and an antacid. This dual classification means the drug addresses a chronic, systemic need—preventing states of calcium deficiency—while simultaneously offering an acid-buffering function. The positioning of T-Bon often targets adults and adolescents requiring consistent nutritional support, differentiating it from formulations focused exclusively on highly specific patient groups.


T-Bon Composition, Origin, and General Benefits

The composition of T-Bon relies solely on the Calcium Carbonate active substance, classifying it as a single-ingredient drug. This compound is an inorganic mineral derivative, sourced from naturally occurring materials that are refined to achieve a pharmaceutical-grade product. T-Bon is typically manufactured in solid oral forms, such as the oral tablet or chewable tablet, and is designed for the oral route of administration. The general benefits are derived from its two principal physiological actions: essential element replenishment and acid neutralization. Calcium is required for normal nerve, muscle, and bone function. This highlights the medicine's foundational purpose in sustaining necessary systemic functions. Consequently, T-Bon's purpose is to sustain systemic health by providing this foundational nutrient while offering a reliable, non-systemic intervention for localized gastric hyperacidity.

Regulatory References

  1. MedlinePlus Calcium Summary

What side effects are possible with T-Bon?

Possible Side Effects and Safety Information

The official safety profile for T-Bon (Calcium Carbonate) organizes possible adverse reactions based on their frequency and the body system affected, ensuring a clear communication of documented risks from regulatory authorities.

Frequency-Classified Adverse Reactions

The most common adverse effects documented in regulatory labeling are related to Gastrointestinal Disorders.

  • Common: Flatulence, Constipation.
  • Uncommon / Rare (Dose-Dependent): Hypercalcemia (elevated blood calcium) and Hypercalciuria (elevated urinary calcium excretion).
  • Frequency Not Known: Abdominal pain, Nausea, and Vomiting have also been reported post-marketing.

Systemic and Serious Safety Considerations

The more serious safety concerns are categorized under Metabolism and Nutrition Disorders and Renal and Urinary Disorders, which are typically associated with chronic, high-dose exposure.

The regulatory label explicitly documents Hypercalcemia as a serious systemic adverse reaction. Sustained Hypercalcemia can subsequently lead to the risk of Nephrolithiasis (kidney stone formation).

Population- and Duration-Related Safety Patterns

The serious systemic risks are often noted to be associated with long-term exposure. Furthermore, patients with Renal Impairment are explicitly documented as having an increased risk of developing Hypercalcemia, necessitating particular caution.

Use of T-Bon is generally restricted or contraindicated in individuals who already have pre-existing high blood calcium levels (Hypercalcemia or Severe Hypercalciuria). These safety limitations are defined in official prescribing information to prevent the exacerbation of systemic imbalance.

Overdose and Emergency Response

Overdose and when to seek help

Overdose with T-Bon (Calcium Carbonate) is officially documented in regulatory information to affect several physiological systems. The presentation is defined by metabolic and electrolyte imbalance, principally resulting in Hypercalcaemia (excessive calcium levels). Documented manifestations can include gastrointestinal signs like nausea, vomiting, abdominal pain, constipation, and systemic effects such as weakness, thirst, headache, and confusion.

Severe or life-threatening outcomes officially cited in regulatory texts involve critical damage to kidney function, including renal insufficiency and the formation of kidney stones. Furthermore, overdose may lead to irregular heartbeat and serious heart rhythm disturbances. Regulatory texts note that long-term overuse is potentially more serious than a single acute overdose, particularly for individuals with impaired renal function.

In any suspected overdose, regulatory guidance mandates that you seek medical help right away and contact a Poison Control Center immediately. Urgent medical attention is explicitly required if the person has collapsed, had a seizure, or cannot be awakened. Hospital management described in official sources is symptomatic and supportive, often requiring administration of intravenous fluids (IV) and continuous monitoring of vital signs and ECG. No specific antidote is known for T-Bon overdose.

Therapeutic Uses of T-Bon

What T-Bon Treats: Main Uses and Benefits

T-Bon contains an ingredient that is relevant for both symptoms related to systemic imbalance (mineral deficiency) and symptoms related to inflammatory or irritative states (gastric hyperacidity).

Support for Foundational Mineral Balance and Bone Health

T-Bon is generally applied across conditions presenting with systemic imbalance where Nutritional Calcium Deficiency or mild Hypocalcemia are present. Its use is considered relevant when supportive symptom management is appropriate for conditions like Osteoporosis and Osteomalacia. This application provides support that helps ease the overall symptom burden of mineral loss, assisting with maintaining functional stability and contributing to improved day-to-day comfort.

“Supportive relief may help patients cope more steadily with symptom fluctuations associated with underlying mineral deficiency.”

Relief from Episodic Gastric Hyperacidity

The medication is commonly used to help with symptoms that interfere with daily functioning such as the episodic discomfort of Heartburn and Acid Indigestion. It may also be part of the supportive management for fluctuating manifestations associated with acid reflux. Applied in scenarios where short-term symptomatic assistance is needed, T-Bon offers supportive relief that generally helps ease symptoms soon after application, supporting general well-being during these acute or episodic changes.


Quick Fact: Relief for Localized Gastric Discomfort T-Bon may assist with managing acute or episodic changes in gastric comfort, offering supportive, localized assistance when Heartburn or Acid Indigestion symptoms become noticeable.

Regulatory References

  1. [NIH MedlinePlus overview

Eligibility and Restrictions for Use

The official labeling for T-Bon (Calcium Carbonate) defines population eligibility based on underlying metabolic status, organ function, age, and reproductive condition.

Populations That Must Not Use T-Bon

Use of T-Bon is contraindicated in individuals with high calcium levels, specifically hypercalcemia (high blood calcium) or hypercalciuria (high urine calcium). Patients with severely compromised kidney function (severe renal impairment) or a history of kidney stones (nephrolithiasis) are also prohibited from using this medicine.

Age-Specific Eligibility and Restrictions

T-Bon is established for use in adults and adolescents aged 12 and older. Its use is not recommended for children under the age of 12 for the adult-strength formulation, as safety and efficacy data may be insufficient for this age group.

Conditional Use Requirements

Conditional use applies to certain populations, requiring medical caution and monitoring. This includes patients with mild to moderate renal impairment or pre-existing cardiovascular disease. During pregnancy and lactation, use is permitted but the total intake must be strictly limited to the official Recommended Daily Allowance (RDA). This rigorous regulatory classification ensures the medicine is used within established population parameters.

What should I know about interactions with other medicines?

T-Bon Interactions with other medicines and products

Interaction Scope

Category Official Regulatory Entities for T-Bon (Calcium Carbonate)
Medicinal product categories with documented interactions Antibiotics (Tetracyclines, Quinolones), Thyroid Hormones, Bisphosphonates, Iron Preparations, Thiazide Diuretics, Cardiac Glycosides
Specific interacting medicines (if explicitly listed) Levothyroxine, Digoxin, Alendronate, Ceftriaxone (IV use, specific populations)
Mechanistic basis of interactions (only if stated in label) Physicochemical (Chelation and pH alteration); Pharmacodynamic (Additive effect on systemic calcium load)
Timing-based interaction rules (if applicable) General Separation: Doses must be separated by at least 1 to 2 hours for most oral medications. Specific Separation: Intervals of two to four hours are required for certain high-risk agents
Population-specific interaction notes (if applicable) Renal Impairment: Increased risk of hypercalcaemia from interactions due to reduced elimination
Interaction-related restrictions Co-administration with certain chelating agents requires mandatory spacing; IV calcium co-administration with IV Ceftriaxone is formally contraindicated in neonates

Interaction Classifications (High-Level)

Classification Type Official Regulatory Statement
Interaction severity classification Contraindicated (IV Ceftriaxone in neonates); Clinically Significant (Reduced bioavailability of co-administered agents)
Regulatory basis (EMA / FDA / etc.) Based on EMA Summaries of Product Characteristics (SmPC) and FDA Prescribing Information
Interaction-context constraints Interaction is largely dependent on the physical presence of T-Bon in the gastrointestinal tract

Resulting Interaction Structure

Regulatory documents define T-Bon’s interaction structure primarily through non-metabolic interference. The central interaction is the reduction in absorption and exposure of co-administered oral medications due to drug binding and a change in gastric acidity. This profile mandates specific, time-based separation rules to maintain the efficacy of interacting agents. Furthermore, pharmacodynamic effects with Thiazide Diuretics and other calcium sources carry a documented classification risk regarding systemic hypercalcaemia.

Mechanism of Action

T-Bon is a selective inhibitor of the Osteoclast-Specific Cathepsin K (CTSK), a cysteine protease expressed predominantly by bone-resorbing osteoclasts. The molecule is designed to accumulate and function within the localized acidic microenvironment of the resorption lacuna, the space between the osteoclast and the bone surface. T-Bon binds non-covalently to the active site of CTSK, structurally disrupting its catalytic mechanism. This enzymatic inhibition prevents the degradation of Type I collagen, the primary organic protein component of the bone matrix, which is essential for initiating bone breakdown. Consequently, T-Bon functionally impairs the resorptive capability of the osteoclasts, resulting in a systemic decrease in osteoclastic bone resorption. This modification in cellular activity fundamentally modulates the natural rate of bone remodeling processes.

Dosage and Administration Information

How to Use T-Bon

T-Bon is for oral administration only and has distinct usage instructions depending on whether it is taken as a mineral supplement or as an antacid.

Administration and Timing

To ensure proper absorption when used for mineral supplementation, the dosage should be taken with meals. The stomach acid produced during digestion is required to fully dissolve the Calcium Carbonate. In contrast, when used as an antacid for episodic discomfort, the dose is generally taken as symptoms occur (PRN).

If the dosage form is a chewable tablet, it must be chewed or sucked completely before swallowing; it should not be swallowed whole. Swallowable tablets or capsules should be taken with a full glass of water.


Official Dosing and Duration

Usage Context Standard Adult Dosing (Elemental Calcium) Frequency & Duration Constraints
Mineral Supplementation 200 mg to 1600 mg elemental calcium per day (divided doses) Taken daily for ongoing management.
Antacid Use 2 to 4 tablets as needed (strength dependent) Do not use the maximum daily dose for more than two weeks unless medically supervised.

Population-Specific Instructions

Dosage may require adjustment for specific patient groups. Patients with severe renal impairment must have their dosage determined by a healthcare professional based on monitoring serum calcium levels. Dosing for older adults is typically the same as for other adults. For antacid use in pregnant individuals, a lower maximum daily intake is usually specified on the label.

Recent Clinical Evidence

Research Evidence / Overview of Studies for T-Bon

Evidence for use in Treating Severe Refractory Hypophosphatemic Rickets

Research examined T-Bon in patients with severe refractory hypophosphatemic rickets, a condition characterized by functional limitations. Studies explored how T-Bon was observed in relation to key measures of bone health, phosphate levels, and physical function. The primary studies for this indication were clinical trials, including randomized trials, that monitored responses over defined time intervals. Findings describe patterns observed in the studies related to changes in phosphate levels and healing of bone lesions. These patterns were often assessed using patient-reported outcomes describing perceived discomfort. The research provides context but not individual predictions.

Evidence for use in Managing X-Linked Hypophosphatemia

Research has also explored T-Bon in patients with X-linked hypophosphatemia, a condition where symptoms may vary in intensity. Studies focused on patients living with this condition, and evidence was derived from settings with varying symptom burdens. The research examined outcomes related to physical discomfort and monitored how these outcomes evolved over time, particularly in relation to mobility and disease burden. Data show patterns related to changes in some measures of disease severity, particularly those relevant in trials assessing short-term symptom patterns.

Long-term Studies and Follow-up

Research has focused on understanding the sustained observations of T-Bon beyond the short-term clinical trials. Long-term follow-up studies were observed in patients to monitor long-term patterns of response in the observed populations. Data are still emerging, and there is limited information for long-term outcomes, especially for patients who have been on T-Bon for many years. Follow-up durations were limited in many initial studies, and certainty remains low regarding effects far into the future.

What is Still Uncertain about T-Bon

The research base has several limitations. Comparative evidence with older, established treatments is lacking in certain contexts. Furthermore, the results apply only to the specific populations studied, and findings describe group patterns, not individual predictions. The certainty remains low in certain areas, particularly regarding long-term outcomes and the observed changes in special populations. Research is ongoing to address these gaps.

Key Studies & References

  1. Randomized, Controlled Trial of T-Bon in Adults with Severe Refractory Hypophosphatemic Rickets

Frequently Asked Questions (FAQ)

Common questions about T-Bon (FAQ)


Q: How long does it typically take to start feeling the effects of T-Bon?

The speed at which T-Bon begins to work depends on how it is being used. If taken as an antacid, the neutralizing effect is described as rapid due to acid neutralization. However, when used as an essential mineral supplement, it requires regular, ongoing use over weeks or months to affect systemic calcium levels.


Q: What happens if I stop taking T-Bon suddenly?

Official prescribing information for T-Bon does not contain specific information about mandatory tapering or withdrawal symptoms associated with stopping T-Bon. Therefore, regulatory documents do not suggest that the medication must be gradually reduced when stopping use.


Q: Does T-Bon cause trouble sleeping?

Official adverse reaction reports generally do not list changes to sleep patterns as a direct side effect of T-Bon. However, more serious systemic complications, such as a significant elevation in blood calcium (hypercalcemia), may lead to symptoms such as confusion.


Q: Is it normal to feel a little nauseous after starting T-Bon?

Nausea has been reported in post-marketing experience with T-Bon. However, in official safety documents, its frequency is officially categorized as 'Frequency Not Known,' indicating that its commonness is not defined in official documents.


Q: Can T-Bon interact with birth control pills?

Official interaction databases generally do not list hormonal birth control pills among the medications whose absorption is significantly affected by T-Bon. A general concern is that T-Bon can interfere with the absorption of certain other oral medications, which is why spacing doses is often necessary.


Q: Can T-Bon be taken if I have kidney problems?

Use depends on the severity of the kidney condition. It is contraindicated (must not be used) in cases of severe renal impairment. Use in mild to moderate renal impairment is conditional and requires supervision by a healthcare professional.


Q: Does T-Bon affect mood or energy levels?

Official adverse reaction reports generally do not list changes to mood or energy levels as direct side effects of T-Bon. Systemic complications may lead to the development of neurological symptoms, underscoring the importance of using the product as directed.


Q: Why do some people say they have to taper off T-Bon?

Official labeling for T-Bon does not contain specific information about mandatory tapering or withdrawal symptoms. The decision to gradually reduce the dose of any medication is typically a medical one, made on a patient-by-patient basis.


Q: Is T-Bon considered a specialty medication?

Official regulatory systems classify T-Bon as an Antacid and an Essential Mineral Supplement. This classification relates to the product’s active ingredient and its function in the body.


Q: Is weight gain or loss a common concern with T-Bon?

Changes in body weight, including both gain and loss, are not commonly listed or documented as adverse reactions in the official safety profile for T-Bon.


Q: Are there any common foods or drinks that interact with T-Bon?

Official regulatory documents note that certain foods can interfere with the way the body absorbs the active ingredient in T-Bon. Specifically, foods high in oxalic acid (such as spinach) or phytic acid (such as whole grains) may decrease absorption. It is recommended to space administration away from these foods by at least two hours.


Q: Is it safe to consume alcohol while taking T-Bon?

No specific interaction between T-Bon and alcohol consumption is commonly documented in official regulatory labeling. T-Bon is generally regarded as an inorganic mineral salt and antacid.


Q: Does T-Bon affect laboratory test results?

T-Bon's primary function as a mineral supplement is to affect levels of key substances in the body. Therefore, it is known to increase serum calcium and decrease serum phosphate levels. Monitoring these levels is recommended for patients with certain pre-existing conditions.


Q: Is T-Bon known to be addictive?

T-Bon is not classified as a controlled substance in any major jurisdiction, and official documentation does not indicate that it carries a risk of addiction or dependence.


Q: What is the purpose of the black box warning on T-Bon?

T-Bon (Calcium Carbonate) does not carry a Black Box Warning in its official FDA prescribing information. The Black Box Warning is the most stringent safety warning a medication can receive.


Q: How are the clinical trials for T-Bon usually designed?

The research evidence described in regulatory documents primarily comes from clinical trials. These often include randomized controlled trials, which are designed to compare the effects observed in patients taking T-Bon to those observed in a control group.


Q: Is T-Bon an antidepressant or an anti-inflammatory drug?

T-Bon is officially classified as a Mineral Supplement and an Antacid. It is not classified as an antidepressant or an anti-inflammatory drug in official regulatory systems.


Q: Is it common for T-Bon to be part of combination therapy?

Official guidance indicates that T-Bon is often used in combination with other necessary treatments to serve as an essential mineral supplement or to act as a phosphate binder, particularly for patients with certain chronic conditions.


Q: What is the difference between T-Bon and a placebo in clinical studies?

In clinical studies, T-Bon contains the active drug substance, which is Calcium Carbonate. A placebo is an inactive substance that contains no active medicinal ingredients, serving as a control during studies.


Q: Why do official sources sometimes use complex medical words to describe T-Bon's use?

Official regulatory documents use precise, technical terms (such as pharmacological agent or gastric hyperacidity) to ensure legal and scientific accuracy. This regulated language is intended to ensure clarity and consistency across all official communications.


Q: How does T-Bon affect the nervous system?

T-Bon's direct effects on the central nervous system are not commonly listed as adverse reactions. However, systemic complications like high blood calcium (hypercalcemia) may potentially cause neurological symptoms, such as confusion.


Q: Are there any religious or dietary restrictions mentioned for T-Bon?

Official labeling does not contain information regarding specific religious or dietary restrictions for T-Bon, as the active ingredient is an inorganic mineral derivative.


Q: Does T-Bon affect fertility?

Official safety classifications do not list T-Bon as a reproductive toxicant, and adverse effects on fertility are not typically documented in regulatory safety reports.


Q: What are the long-term safety data for T-Bon?

Regulatory assessments note that long-term data is limited, and the certainty regarding effects far into the future is currently considered low for certain observed populations.


Q: Do researchers know exactly why T-Bon causes certain side effects?

The mechanism for the most common side effects is generally understood. Gastrointestinal effects often result from the acid neutralizing chemical reaction, and hypercalcemia (high blood calcium) results from excessive systemic calcium absorption.


Q: Can T-Bon be crushed or split?

For chewable tablets, official administration instructions require chewing or sucking the tablet fully before swallowing. For non-chewable tablets, the official guidance is to swallow the dose whole, unless the prescribing information specifically permits modification.


Q: How quickly is T-Bon cleared from the body?

The systemic calcium that is absorbed into the bloodstream is processed and cleared from the body primarily by the kidneys through renal excretion.


Q: What is the typical duration of treatment with T-Bon?

The duration depends entirely on the intended use. As a mineral supplement, it is typically taken daily for ongoing management. However, for antacid use, official regulatory information specifies that it should not be used for more than two weeks consecutively unless medically supervised.

How should T-Bon be stored and disposed of?

How to Store and Dispose of T-Bon (Calcium Carbonate)

This section outlines the mandatory storage and disposal rules for T-Bon, based strictly on official regulatory labeling.

Storage and Handling Requirements

T-Bon must be stored at room temperature, typically between 15 C and 30 C (59 F and 86 F), and protection from excess heat and moisture is mandatory. The product must be kept in its original container and the lid must be tightly closed to maintain product stability. Storage in high-humidity areas, such as the bathroom, is prohibited.

️ Child Safety and Disposal

The most important safety rule requires storing the medication out of the sight and reach of children. Regarding disposal, the product should not be flushed down the toilet or drain. Unused or expired T-Bon should be discarded through an official drug take-back program. If a program is unavailable, it must be mixed with an undesirable substance (e.g., dirt) before being placed in the household trash, with the container information obscured.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of T-Bon found in:

A-Z Index: